Business
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
-First patient dosed with JANX007 in first-in-human Phase 1 clinical trial in prostate cancer patients- -Interim clinical update from Phase 1 trial of
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n-First patient dosed with JANX007 in first-in-human Phase 1 clinical trial in prostate cancer patients-\n\n-Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023-\n\n-IND application for EGFR-TRACTr (JANX008) remains on-track to be submitted in 2H 2022-\n\n-Management team and Board strengthened with key appointments-\n\n-Participating in upcoming virtual fireside chat-\n\n-$338.8 million in cash and cash equivalents and short-term investments at end of third quarter 2022-\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.\n\n“We recently reached our most important milestone by dosing our first patient. At Janux we operate under the tenet that every day matters for cancer patients, and our ability to rapidly move our lead PSMA-TRACTr into the clinic to provide needed treatments for these patients exemplifies this principle,” said David Campbell, Ph.D., President and CEO of Janux.\n\nRECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:\n\nJanux has prioritized its programs to enable sufficient funding to provide key clinical data assessments for its lead programs.\n\n\nFirst patient dosed with lead program (JANX007) in first-in-human Phase 1 clinical trial in prostate cancer patients.\n\n\nThe Phase 1 clinical trial is a multi-center, open-label dose escalation trial to evaluate ascending doses of JANX007 in patients with mCRPC. This trial is assessing the safety, tolerability, pharmacokinetic, pharmacodynamic, and the preliminary efficacy of JANX007 as a single agent in adult subjects with mCRPC. For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT05519449.\n\n\n\n\n\nCGMP manufacturing of EGFR-TRACTr (JANX008) drug substance and drug product has been completed and the material released to support the IND and supply first-in-human clinical trials.\n\n\n\nInitiated CGMP manufacturing of PD-L1xCD28 TRACIr (JANX009) and on-track for production and release of drug substance and drug product ...